Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agilon Health (AGL) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Agilon Health (AGL) over the last 6 years, with Q3 2025 value amounting to $7.4 million.

  • Agilon Health's Depreciation & Amortization (CF) rose 1949.18% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 2164.3%. This contributed to the annual value of $24.5 million for FY2024, which is 2133.82% up from last year.
  • Latest data reveals that Agilon Health reported Depreciation & Amortization (CF) of $7.4 million as of Q3 2025, which was up 1949.18% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, Agilon Health's Depreciation & Amortization (CF) ranged from a high of $7.4 million in Q3 2025 and a low of $3.0 million during Q2 2022
  • For the 5-year period, Agilon Health's Depreciation & Amortization (CF) averaged around $5.0 million, with its median value being $5.1 million (2023).
  • Per our database at Business Quant, Agilon Health's Depreciation & Amortization (CF) plummeted by 1582.73% in 2022 and then surged by 8129.52% in 2023.
  • Quarter analysis of 5 years shows Agilon Health's Depreciation & Amortization (CF) stood at $3.6 million in 2021, then rose by 7.39% to $3.9 million in 2022, then surged by 31.74% to $5.1 million in 2023, then increased by 26.17% to $6.5 million in 2024, then rose by 14.41% to $7.4 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $7.4 million for Q3 2025, versus $7.3 million for Q2 2025 and $6.9 million for Q1 2025.